Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Richard Dutton

General Anesthesiology · UMSOM

View

Dr. Jed Wolpaw

General Anesthesiology · Johns Hopkins

View

Dr. Adriana Posada Londono

General Anesthesiology · Inova Fairfax Hospital

View

Dr. Yuriy Bronshteyn

General Anesthesiology · Duke

View

Dr. Matt Sherrer

Perioperative Med · UAB

View

Dr. Nancy Oriol

OB Anesthesia · BIDMC

View

Dr. Raj Gupta

Regional Anesthesiology · VUMC

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.

    Mar 15, 2024DOI: 10.1016/j.cardfail.2024.02.020Journal ArticleJCF

    Written by: Ahmad MasriMark V SherridTheodore P AbrahamLubna ChoudhuryPablo Garcia-PaviaChristopher M KramerRoberto Barriales-VillaAnjali T OwensFlorian RaderSherif F NaguehIacopo OlivottoSara SaberiAlbree Tower-RaderTimothy C WongCaroline J CoatsHugh WatkinsMichael A FiferScott D SolomonStephen B HeitnerDaniel L JacobyStuart KupferFady I MalikLisa MengRegina L SohnAmy WohltmanMartin S MaronREDWOOD-HCM Investigators

    Summary

    BACKGROUND: This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM).METHODS: Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤ 30 mmHg, left ventricular ejection fraction [LVEF] ≥ 60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] > 300 pg/mL) received aficamten 5-15 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks.RESULTS: We enrolled 41 patients (mean ± SD age 56 ± 16 years; 59% female). At Week 10, 22 (55%) patients experienced an improvement of ≥ 1 New York Heart Association class; 11 (29%) became asymptomatic. Clinically relevant improvements in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores occurred in 22 (55%) patients. Symptom relief was paralleled by reductions in NT-proBNP levels (56%; P < 0.001) and high-sensitivity cardiac troponin I (22%; P < 0.005). Modest reductions in LVEF (mean ± SD) of -5.4% ± 10 to 64.6% ± 9.1 were observed. Three (8%) patients had asymptomatic reduction in LVEF < 50% (range: 41%-48%), all returning to normal after 2 weeks of washout. One patient with prior history of aborted sudden cardiac death experienced a fatal arrhythmia during the study.CONCLUSIONS: Aficamten administration for symptomatic nHCM was generally safe and was associated with improvements in heart failure symptoms and cardiac biomarkers.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04219826.
    CWDr. Caroline Wong

    Dr. Caroline Wong

    Anesthesiology · General Anesthesiology
    NYU Langone Health
    carolinew